Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (vol 10, e004291, 2022)

被引：0
|
作者：
Liu, J.
Yang, Y.
Liu, Z.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷 / 06期
关键词：
D O I：
10.1136/jitc-2021-004291corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.
    Li, Jingpei
    Liu, Jun
    Li, Zhuoyi
    Cui, Fei
    Zeng, Yuan
    Liang, Wenhua
    Liang, Hengrui
    Wang, Wei
    Xu, Ke
    Cai, Weipeng
    Fu, JunHui
    He, Jianxing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
    Xing, Wenqun
    Zhao, Lingdi
    Fu, Xiaomin
    Liang, Guanghui
    Zhang, Yong
    Yuan, Dongfeng
    Li, Zhenxuan
    Gao, Quanli
    Zheng, Yan
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (11) : 6861 - 6867
  • [33] The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma
    Xu, Weili
    Jiang, Youhua
    Wang, Changchun
    Wu, Jie
    Li, Jianqiang
    Hu, Yuqian
    Lu, Weishan
    Shen, Dijian
    Wang, Yinjie
    Chen, Qixun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial
    Meng, Xiangrui
    Qi, Yu
    Shan, Zhengzheng
    Yang, Yang
    Fan, Qingxia
    Wang, Feng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study
    He, Yifu
    Li, Chenghui
    Zhang, Fenglin
    Hu, Bing
    Sun, Yubei
    Xia, Xiaoyang
    Zhang, Yanshun
    Wang, Gang
    Xu, Tengyun
    Duan, Aixiong
    Wu, Shusheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [36] Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial
    Guo, Wei
    Wang, YingJian
    He, Yan
    Li, Kunkun
    Bao, Tao
    He, Xiandong
    Xie, Xianfeng
    Chen, Xv
    Pu, Xiangshu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
    Ding, Chengzhi
    Guo, Yijun
    Zhou, Yaning
    He, Yi
    Chen, Chunji
    Zhang, Ming
    Guo, Xufeng
    [J]. BMC CANCER, 2023, 23 (01)
  • [38] Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
    Chengzhi Ding
    Yijun Guo
    Yaning zhou
    Yi He
    Chunji Chen
    Ming Zhang
    Xufeng Guo
    [J]. BMC Cancer, 23
  • [39] Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
    Zhang, Zhi
    Ye, Jinjun
    Li, Hui
    Gu, Dayong
    Du, Mingyu
    Ai, Dashan
    Chen, Wei
    Fang, Ying
    Xu, Xinyu
    Bai, Chenguang
    Zhao, Kuaile
    Zhou, Guoren
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [40] Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study
    Park, Sehhoon
    Lee, Yurimi
    Lee, Jiyun
    Min, Yang Won
    Kim, Hong Kwan
    Choi, Joon Young
    Jung, Hyun Ae
    Choi, Yong Soo
    Choi, Yoon-La
    Shim, Young Mog
    Sun, Jong-Mu
    [J]. CANCER RESEARCH AND TREATMENT, 2024, 56 (02):
12345